From private incentives to public health need: rethinking research and development for pandemic preparedness.
Torreele E., Wolfe D., Kazatchkine M., Sall A., Ruxrungtham K., Fitchett JRA., Liu J., Kobinger G., Vaca-González C., Gómez C., Terblanche P., Swaminathan S., Olliaro P., Clark H.
Pandemic preparedness and response have relied primarily on market dynamics to drive development and availability of new health products. Building on calls for transformation, we propose a new value proposition that instead prioritises equity from the research and development (R&D) stage and that strengthens capacity to control outbreaks when and where they occur. Key elements include regional R&D hubs free to adapt well established technology platforms, and independent clinical trials networks working with researchers, regulators, and health authorities to better study questions of comparative benefit and real-world efficacy. Realising these changes requires a shift in emphasis: from pandemic response to outbreak control, from one-size-fits-all economies of scale to R&D and manufacture for local need, from de novo product development to last-mile innovation through adaptation of existing technologies, and from proprietary, competitive R&D to open science and financing for the common good that supports collective management and sharing of technology and know-how.